Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Allogeneic CAR NK Cell Therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):